{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Com&page=3", "query": { "intervention": "Com", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 297, "total_pages": 30, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Com&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Com&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T06:53:10.678Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002704", "title": "Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "asparaginase", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "liposomal cytarabine", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "low-LET electron therapy", "type": "RADIATION" }, { "name": "low-LET photon therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "20 Years", "sex": "ALL", "summary": "Up to 20 Years" }, "enrollment_count": 156, "start_date": "1996-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-01", "last_synced_at": "2026-10-19T06:53:10.678Z", "location_count": 62, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002704" }, { "nct_id": "NCT00002816", "title": "Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "thioguanine", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "low-LET cobalt-60 gamma ray therapy", "type": "RADIATION" }, { "name": "low-LET electron therapy", "type": "RADIATION" }, { "name": "low-LET photon therapy", "type": "RADIATION" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "20 Years", "sex": "ALL", "summary": "Up to 20 Years" }, "enrollment_count": 120, "start_date": "1996-12", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2013-08-22", "last_synced_at": "2026-10-19T06:53:10.678Z", "location_count": 30, "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 23 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002816" }, { "nct_id": "NCT04536922", "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic HPV-16 Positive Squamous Cell Anal Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA(R))", "type": "DRUG" }, { "name": "Individual Patient TCR-Transduced PBL", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2021-01-27", "completion_date": "2021-01-27", "has_results": false, "last_update_posted_date": "2021-02-01", "last_synced_at": "2026-10-19T06:53:10.678Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04536922" }, { "nct_id": "NCT05303792", "title": "Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 68, "start_date": "2023-06-09", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-19T06:53:10.678Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Irvine, California • Orange, California + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05303792" }, { "nct_id": "NCT05319457", "title": "Testing Radon Com Methods: Clinical Trial Smartphone App vs Print Brochures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "The radon app", "type": "OTHER" }, { "name": "Print brochure", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of North Dakota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2022-05-05", "completion_date": "2022-09-01", "has_results": false, "last_update_posted_date": "2022-11-02", "last_synced_at": "2026-10-19T06:53:10.678Z", "location_count": 1, "location_summary": "Grand Forks, North Dakota", "locations": [ { "city": "Grand Forks", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05319457" }, { "nct_id": "NCT00580372", "title": "UARK 89-001 Phase II Study of Intensive \"TOTAL THERAPY\" For Untreated or Minimally Treated Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "VAD", "type": "DRUG" }, { "name": "High-Dose cyclophosphamide", "type": "DRUG" }, { "name": "Hemopoietic stem cell procurement", "type": "PROCEDURE" }, { "name": "EDAP", "type": "DRUG" }, { "name": "Autologous Hemopoietic Stem Cell Transplant 1", "type": "PROCEDURE" }, { "name": "Autologous Hemopoietic Stem Cell Transplant 2", "type": "PROCEDURE" }, { "name": "Maintenance", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 231, "start_date": "2002-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-09-20", "last_synced_at": "2026-10-19T06:53:10.678Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580372" }, { "nct_id": "NCT00393029", "title": "Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anti-p53 TCR-Gene" ], "interventions": [ { "name": "anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2006-10", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2011-08-15", "last_synced_at": "2026-10-19T06:53:10.678Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00393029" }, { "nct_id": "NCT04318678", "title": "CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AML/MDS", "B-ALL", "T-ALL", "BPDCN" ], "interventions": [ { "name": "CD123-CAR T", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 108, "start_date": "2020-07-29", "completion_date": "2030-07-29", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-19T06:53:10.678Z", "location_count": 2, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04318678" }, { "nct_id": "NCT04881240", "title": "Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphoblastic Leukemia, Refractory", "Pediatric ALL" ], "interventions": [ { "name": "CD19-CAR(Mem) T-cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "CliniMACS", "type": "DEVICE" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 60, "start_date": "2024-02-14", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-19T06:53:10.678Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04881240" }, { "nct_id": "NCT00671658", "title": "Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide (CTX)", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Pegylated asparaginase", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Solumedrol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 220, "start_date": "2002-11", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2020-12-03", "last_synced_at": "2026-10-19T06:53:10.678Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671658" } ] }